Cargando…

MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review

The alterations of MET have been detected in non-small-cell lung cancer (NSCLC). However, survival benefit of MET inhibitors remains controversial. We performed this meta-analysis to evaluate the survival benefit of MET inhibitors combined with an epidermal growth factor receptor tyrosine kinase inh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Jung Han, Kim, Hyeong Su, Kim, Bum Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Meta-Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650440/ https://www.ncbi.nlm.nih.gov/pubmed/29088885 http://dx.doi.org/10.18632/oncotarget.20824

Ejemplares similares

Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Survival benefit of immune checkpoint inhibitors according to the histology in non-small-cell lung cancer: A meta-analysis and review
por: Kim, Bum Jun, et al.
Publicado: (2017)

Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

Clinicopathological impacts of high c-Met expression in renal cell carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Prognostic value of c-Met overexpression in pancreatic adenocarcinoma: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
por: Kim, Bum Jun, et al.
Publicado: (2017)

The role of anti-EGFR agents in patients with locoregionally advanced head and neck cancer: a meta-analysis of randomized trials
por: Kim, Bum Jun, et al.
Publicado: (2017)

Survival benefit of anti-angiogenic agents in patients with previously treated advanced gastric or gastroesophageal junction cancer: a meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2017)

The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials
por: Jang, Hyun Joo, et al.
Publicado: (2017)

Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review
por: Kim, Jung Han, et al.
Publicado: (2017)

Adjuvant Chemotherapy for Advanced Gastric Cancer in Elderly and Non-elderly Patients: Meta-Analysis of Randomized Controlled Trials
por: Chang, Seong-Hwan, et al.
Publicado: (2017)

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer
por: Costa, Rubens Barros, et al.
Publicado: (2018)

Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis
por: Cavanna, Luigi, et al.
Publicado: (2019)

Efficacy and safety of immune checkpoint inhibitors for advanced non-small cell lung cancer with or without PD-L1 selection: A systematic review and network meta-analysis
por: Li, Yan, et al.
Publicado: (2023)

Meta-analysis of the incidence and risks of interstitial lung disease and QTc prolongation in non-small-cell lung cancer patients treated with ALK inhibitors
por: Lin, Liping, et al.
Publicado: (2017)

Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors
por: Li, Nijiao, et al.
Publicado: (2023)

Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis
por: De Mello, Ramon Andrade, et al.
Publicado: (2017)

Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
por: Alanazi, Abdullah, et al.
Publicado: (2020)

Systematic review and meta-analysis of third-line salvage therapy for the treatment of advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
por: Zhang, Nan, et al.
Publicado: (2018)

Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
por: Wen, Yaokai, et al.
Publicado: (2022)

Incidence and risk of hepatic toxicities associated with anaplastic lymphoma kinase inhibitors in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Liu, Bing, et al.
Publicado: (2017)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Long non-coding RNAs function as novel predictors and targets of non-small cell lung cancer: a systematic review and meta-analysis
por: Xiong, Yanlu, et al.
Publicado: (2018)

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy
por: Wu, Di, et al.
Publicado: (2017)

Clinicopathological significance of CHFR methylation in non-small cell lung cancer: a systematic review and meta-analysis
por: Wang, Chen, et al.
Publicado: (2017)

The efficacy and safety of paclitaxel and carboplatin with versus without bevacizumab in patients with non-small-cell lung cancer: a systematic review and meta-analysis
por: Han, Shiqian, et al.
Publicado: (2017)

Adoptive immunotherapy shows encouraging benefit on non-small cell lung cancer: a systematic review and meta-analysis
por: Zhao, Binghao, et al.
Publicado: (2017)

Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis
por: Soo, Ross A., et al.
Publicado: (2018)

Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis
por: Chen, Dongjie, et al.
Publicado: (2022)

Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis
por: Zhu, Yixiang, et al.
Publicado: (2023)

The Prognostic Value of Periostin Expression in Non-Small Cell Lung Cancer: A Meta-Analysis
por: Li, Mengjie, et al.
Publicado: (2022)

Network meta-analysis of immune-oncology monotherapy as first-line treatment for advanced non-small-cell lung cancer in patients with PD-L1 expression ⩾50%
por: Freemantle, Nick, et al.
Publicado: (2022)

Docetaxel versus docetaxel plus cisplatin for non-small-cell lung cancer: a meta-analysis of randomized clinical trials
por: Li, Ang, et al.
Publicado: (2017)

On-demand Versus Continuous Maintenance Treatment of Gastroesophageal Reflux Disease With Proton Pump Inhibitors: A Systematic Review and Meta-analysis
por: Kang, Seung Joo, et al.
Publicado: (2022)

Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials
por: Zhang, Xiao-Nan, et al.
Publicado: (2017)

Prognostic value of postoperative ctDNA detection in patients with early non-small cell lung cancer: a systematic review and meta-analysis
por: Guo, Kaibo, et al.
Publicado: (2023)

Can peripheral blood be used as surrogate in detecting epidermal growth factor receptor mutation status in advanced non-small cell lung cancer patients? A meta-analysis
por: Mao, Xiaowei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rad4k09pqsoeqhl5t9qr577ok7